Biocon’s pertuzumab biosimilar gets positive EMA CHMP opinion recommendation
Biocon Biologics says EMA CHMP issued a positive opinion recommending approval for its pertuzumab biosimilar under a tailored clinical approach.
BENGALURU, India, Sept. 22, 2026 // -- Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited (BSE: 532523) (NSE:BIOCON), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion reco…